Atai life sciences reports second quarter 2023 financial results and operational highlights, and announces clinical data from the phase 1 study of dmx-1002 (ibogaine)

New york and berlin, aug. 10, 2023 (globe newswire) -- atai life sciences (nasdaq: atai) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported second quarter 2023 financial results and provided corporate updates.

ATAI Ratings Summary

ATAI Quant Ranking